Equillium, Inc.
Equillium, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $41.1 million, up 13.9% from fiscal 2023. In the quarter to June 2026, revenue fell 52.3%, EPS grew 75.0% and free cash flow fell 38.7%, each against the same quarter a year earlier. Dividend growth for three consecutive years, revenue growth for three.
Follow EQ
Equillium, Inc. (EQ) EV/Sales
As of 9 October 2026, Equillium, Inc. (EQ) trades at a EV/Sales of 2.7×. Over the past ten years it has ranged from −0.5× (November 2023) to 7.5× (June 2026); the current reading is higher than 94% of that period. That is below the Biotechnology industry median of 10.2× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 0.3× | — |
| FY2023 | −0.2× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2024 | 0.3× | 15.96% |
| Sep 2024 | 0.2× | — |
| Jun 2024 | 0.0× | — |
| Mar 2024 | 1.3× | — |
| 5 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MIST Milestone Pharmaceuticals Inc. compare | −0.9× |
| OKUR OnKure Therapeutics, Inc. compare | n/m |
| NMRA Neumora Therapeutics, Inc. compare | n/m |
| VXRT VAXART, INC. compare | 0.2× |
| CLLS Cellectis S.A. compare | 0.5× |
| EQ Equillium, Inc. | 2.7× |
| ICCC ImmuCell Corporation compare | 2.8× |
| RLYB Rallybio Corporation compare | 4.8× |
| ATRA Atara Biotherapeutics, Inc. compare | 21.3× |
| Biotechnology industry median | 10.2× |
| Healthcare sector median | 3.6× |
| Market median | 2.2× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)